Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Breast cancer, specifically metastatic breast, is a leading cause of morbidity and mortality in women. This is mainly due to relapse and reoccurrence of tumor. The primary reason for cancer relapse is the development of multidrug resistance (MDR) hampering the treatment and prognosis. MDR can occur due to a multitude of molecular events, including increased expression of efflux transporters such as P-gp, BCRP, or MRP1; epithelial to mesenchymal transition; and resistance development in breast cancer stem cells. Excessive dose dumping in chemotherapy can cause intrinsic anti-cancer MDR to appear prior to chemotherapy and after the treatment. Hence, novel targeted nanomedicines encapsulating chemotherapeutics and gene therapy products may assist to overcome cancer drug resistance. Targeted nanomedicines offer innovative strategies to overcome the limitations of conventional chemotherapy while permitting enhanced selectivity to cancer cells. Targeted nanotheranostics permit targeted drug release, precise breast cancer diagnosis, and importantly, the ability to overcome MDR. The article discusses various nanomedicines designed to selectively target breast cancer, triple negative breast cancer, and breast cancer stem cells. In addition, the review discusses recent approaches, including combination nanoparticles (NPs), theranostic NPs, and stimuli sensitive or “smart” NPs. Recent innovations in microRNA NPs and personalized medicine NPs are also discussed. Future perspective research for complex targeted and multi-stage responsive nanomedicines for metastatic breast cancer is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162 · cited 1×
“The clonal evolution model postulates that random mutation, along with clonal selection at the genetic level, give rise to the cancer cellular heterogeneity commonly observed in breast cancer [5,6].”
BackgroundKnocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · cited 1×
“Nucleases present in the blood circulation can easily degrade naked siRNA and gene therapy products and significantly reduce their t 1/2 (<15 min) [103].”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 1×
“This transporter was first discovered while studying the H69AR cell line, which is a small cell lung cancer drug-resistant line [50,51].”
BackgroundHarbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164 · cited 1×
“) route and have difficulty with effective dissolution and release of the drug from the tumor site [101,102].”
BackgroundExploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · cited 2×
“This therapy is based on combining and delivering chemotherapy drugs that work by non-overlapping molecular mechanisms, thus, reducing MDR occurrence and maximizing tumor killing [211].”
BackgroundThomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597
Advances in redox-responsive drug delivery systems of tumor microenvironment
Guo, X., Cheng, Y., Zhao, X., Luo, Y., Chen, J., & Yuan, W.-E. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0398-2 · Cited by 459
Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Chen, J., Imanaka, N., Chen, J., & Griffin, J. D. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605486 · Cited by 346 · cited 18×
“Hypoxia also affects the expression of cadherins to promote EMT via the expression of cyclooxygenase-2 [95].”
BackgroundInfluentialDevulapally, R., Sekar, N. M., Sekar, T. V., Foygel, K., Massoud, T. F., Willmann, J. K., & Paulmurugan, R. (2015) · ACS Nano · doi:10.1021/nn507465d · Cited by 260 · cited 2×
“These NPs showed higher TNBC tumor inhibition in vivo than the scrambled peptide decorated NPs [231].”
BackgroundLv, Y., Xu, C., Zhao, X., Lin, C., Yang, X., Xin, X., Zhang, L., Qin, C., Han, X., Yang, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08051 · Cited by 235
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201 · cited 1×
“Paclitaxel and cisplatin encapsulated in poly (2-oxazoline) polymeric micelles showed improved drug release, drug loading, pharmacokinetics, and efficacy in MDR breast cancer LCC-6MDR orthotopic tumor model and MDR human ovarian carcinoma xenograft tumor [216].”
BackgroundWu, Y., Zhang, Y., Zhang, W., Sun, C., Wu, J., & Tang, J. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.11.041 · Cited by 100
Li, X., Yang, X., Lin, Z., Wang, D., Mei, D., He, B., Wang, X., Wang, X., Zhang, Q., & Gao, W. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.04.018 · Cited by 56 · cited 1×
“PEG-PLA/PHISPEG pH sensitive micelles Folic acid (Folate receptor) Doxorubicin MCF-7/ADR—multidrug-resistant human breast-cancer In vivo [153]”
BackgroundCheng, X., Zeng, X., Zheng, Y., Fang, Q., Wang, X., Wang, J., & Tang, R. (2020) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.01.029 · Cited by 41
Cited by
Sarkar, R., Biswas, S., Ghosh, R., Samanta, P., Pakhira, S., Mondal, M., Dutta Gupta, Y., Bhandary, S., Saha, P., Bhowmik, A., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02518-0 · Cited by 69
Samad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100268 · Cited by 35
Metadata
- Authors
- Gote, V., Nookala, A. R., Bolla, P. K., & Pal, D.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-28
- Volume
- 22
- Issue
- 9
- Pages
- 4673
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3158359283
- Cited by
- 166
- References
- 23
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.